Drug Trial Radar · NCT02285036
Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children
Last checked: Nov 19, 2026Latest source record: Nov 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,660
Actual
Start
Sep 2012
Primary completion
Dec 2012
Study completion May 2013
Sponsor
- Lead sponsor
- Walvax Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Guangxi Center for Disease Control and Prevention; Air Force Military Medical University, China
- First posted
- Nov 6, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A newly 23-valent pneumococcal polysaccharide vaccine was developed with promising safety and immunogenicity demonstrated in the phase III trial in China. A large scale, double blind, randomized, PNEUMOVAX 23 (Merck \& Co., Inc.) controlled phase 3 clinical trial was conducted.
Conditions
- Pneumococcal Infectious Diseases
Interventions
vaccination PPV23Biological
All eligible participants were stratified into four age strata namely, 2 to 6 years, 7 to 17 years, 18 to 59 years and more than 60 years. Stratified, block randomization with a size of eight was applied. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1. Blood samples were obtained from each subject at baseline, day 30-35 after injection, to evaluate immunogenicity.
vaccination PNEUMOVAX 23Biological
Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- the rate of 2-fold increase of anti-pneumococcal antibodyTime frame: 30 days after the injection of vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangxi Provincial Center for Diseases Control and Prevention
Nanning, Guangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.